On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their partnership over alleged “deceptive marketing,” CEO Andrew Dudum said in his ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Investors, CEOs and commentators trashed Hims & Hers founder and CEO Andrew Dudum on social media Wednesday after he praised the "moral courage" of the anti-Israel protesters creating havoc on ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its personalized healthcare solutions and momentum in weight loss offerings.

Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market.

Kevin O'Leary sounded off on Hims & Hers CEO Andrew Dudum over his initial support of the anti-Israel protests and said he would have been fired in seconds if he worked for him.

Andrew Dudum, the Palestinian American CEO of Hims, a telehealth and online pharmacy known for its suggestive New York City subway ads, shared a link to current openings and encouraged the student ...